Improved characterization of the pharmacokinetics of acalabrutinib and its pharmacologically active metabolite, ACP‐5862, in patients with B‐cell malignancies and in healthy subjects using a population pharmacokinetic approach
Open Access
- 21 August 2021
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 88 (2), 846-852
- https://doi.org/10.1111/bcp.14988
Abstract
This analysis aimed to describe the pharmacokinetics (PK) of acalabrutinib and its active metabolite, ACP-5862. A total of 8935 acalabrutinib samples from 712 subjects and 2394 ACP-5862 samples from 304 subjects from 12 clinical studies in patients with B-cell malignancies and healthy subjects were analyzed by non-linear mixed-effects modelling. Acalabrutinib PK was characterized by a two-compartment model with first-order elimination. The large variability in absorption was adequately described by transit compartment chain and first-order absorption, with between-occasion variability on the mean transit time and relative bioavailability. The PK of ACP-5862 was characterized by a two-compartment model with first-order elimination, and the formation rate was defined as the acalabrutinib clearance multiplied by the fraction metabolized. Health status, Eastern Cooperative Oncology Group performance status, and co-administration of proton pump inhibitors were significant covariates. However, none of the investigated covariates led to clinically meaningful changes in exposure, supporting a flat dosing of acalabrutinib.This publication has 9 references indexed in Scilit:
- Exposure–response analysis of acalabrutinib and its active metabolite, ACP‐5862, in patients with B‐cell malignanciesBritish Journal of Clinical Pharmacology, 2021
- Improved characterization of the pharmacokinetics of acalabrutinib and its pharmacologically active metabolite, ACP‐5862, in patients with B‐cell malignancies and in healthy subjects using a population pharmacokinetic approachBritish Journal of Clinical Pharmacology, 2021
- THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Introduction and Other Protein TargetsBritish Journal of Pharmacology, 2019
- Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part II. A mechanistic PBPK model for IR formulation comparison, proton pump inhibitor drug interactions, and administration with acidic juicesEuropean Journal of Pharmaceutics and Biopharmaceutics, 2019
- Abstract 2194: Preclinical pharmacological profiling of ACP-5862, the major metabolite of the covalent BTK inhibitor acalabrutinib, displays intrinsic BTK inhibitory activityCancer Research, 2019
- Population Pharmacokinetics of the BTK Inhibitor Acalabrutinib and its Active Metabolite in Healthy Volunteers and Patients with B-Cell MalignanciesClinical Pharmacokinetics, 2018
- Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency ProfileThe Journal of pharmacology and experimental therapeutics, 2017
- Population pharmacokinetic analysis of varenicline in adult smokersBritish Journal of Clinical Pharmacology, 2009
- Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and SolutionsThe AAPS Journal, 2009